SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, case-control design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months-4 years during July 1, 2022-September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%-60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19-associated ED visits and hospitalization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
MMWR. Morbidity and mortality weekly report - 72(2023), 48 vom: 01. Dez., Seite 1300-1306 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tannis, Ayzsa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 27.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.15585/mmwr.mm7248a2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365239690 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365239690 | ||
| 003 | DE-627 | ||
| 005 | 20240327235502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15585/mmwr.mm7248a2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM365239690 | ||
| 035 | |a (NLM)38032834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tannis, Ayzsa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, case-control design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months-4 years during July 1, 2022-September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%-60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19-associated ED visits and hospitalization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Englund, Janet A |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Ariana |e verfasserin |4 aut | |
| 700 | 1 | |a Harker, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Staat, Mary Allen |e verfasserin |4 aut | |
| 700 | 1 | |a Schlaudecker, Elizabeth P |e verfasserin |4 aut | |
| 700 | 1 | |a Halasa, Natasha B |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Laura S |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Michaels, Marian G |e verfasserin |4 aut | |
| 700 | 1 | |a Selvarangan, Rangaraj |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Jennifer E |e verfasserin |4 aut | |
| 700 | 1 | |a Sahni, Leila C |e verfasserin |4 aut | |
| 700 | 1 | |a Boom, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Weinberg, Geoffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Szilagyi, Peter G |e verfasserin |4 aut | |
| 700 | 1 | |a Clopper, Benjamin R |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yingtao |e verfasserin |4 aut | |
| 700 | 1 | |a McMorrow, Meredith L |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Eileen J |e verfasserin |4 aut | |
| 700 | 1 | |a Moline, Heidi L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t MMWR. Morbidity and mortality weekly report |d 1984 |g 72(2023), 48 vom: 01. Dez., Seite 1300-1306 |w (DE-627)NLM012594334 |x 1545-861X |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:48 |g day:01 |g month:12 |g pages:1300-1306 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15585/mmwr.mm7248a2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 48 |b 01 |c 12 |h 1300-1306 | ||